Related Experiment Video
Updated: Jun 21, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for
Giorgia Nicolini1, Alessandro Clivio, Antonella Fogliata
1Oncology Institute of Southern Switzerland, Medical Physics Unit, Bellinzona, Switzerland. giorgia.nicolini@eoc.ch
Purpose:
A study was performed comparing dosimetric characteristics of volumetric modulated arcs (RapidArc, RA) and fixed field intensity modulated therapy (IMRT) on patients with bilateral breast carcinoma.
Materials And Methods:
Plans for IMRT and RA, were optimised for 10 patients prescribing 50 Gy to the breast (PTVII, 2.0 Gy/fraction) and 60 Gy to the tumour bed (PTVI, 2.4 Gy/fraction). Objectives were: for PTVs V(90%)>95%, D(max)<107%; Mean lung dose MLD<15 Gy, V(20Gy)<22%; heart involvement was to be minimised. The MU and delivery time measured treatment efficiency. Pre-treatment dosimetry was performed using EPID and a 2D-array based methods.
Results:
For PTVII minus PTVI, V(90%) was 97.8 +/- 3.4% for RA and 94.0 +/- 3.5% for IMRT (findings are reported as mean +/- 1 standard deviation); D(5%)-D(95%) (homogeneity) was 7.3 +/- 1.4 Gy (RA) and 11.0 +/- 1.1 Gy (IMRT). Conformity index (V(95%)/V(PTVII)) was 1.10 +/- 0.06 (RA) and 1.14 +/- 0.09 (IMRT). MLD was <9.5 Gy for all cases on each lung, V(20Gy) was 9.7 +/- 1.3% (RA) and 12.8 +/- 2.5% (IMRT) on left lung, similar for right lung. Mean dose to heart was 6.0 +/- 2.7 Gy (RA) and 7.4 +/- 2.5 Gy (IMRT). MU resulted in 796 +/- 121 (RA) and 1398 +/- 301 (IMRT); the average measured treatment time was 3.0 +/- 0.1 minutes (RA) and 11.5 +/- 2.0 (IMRT). From pre-treatment dosimetry, % of field area with gamma <1 resulted 98.8 +/- 1.3% and 99.1 +/- 1.5% for RA and IMRT respectively with EPID and 99.1 +/- 1.8% and 99.5 +/- 1.3% with 2D-array (DeltaD = 3% and DTA = 3 mm).
Conclusion:
RapidArc showed dosimetric improvements with respect to IMRT, delivery parameters confirmed its logistical advantages, pre-treatment dosimetry proved its reliability.

